Skip to content

Survey on the actual state of Augmentation Therapy with Atypical Antipsychotics in the Treatment of Depression -A study using a Japanese health insurance claims database -

Survey on the actual state of Augmentation Therapy with Atypical Antipsychotics in the Treatment of Depression -A study using a Japanese health insurance claims database - - Survey on the actual state of Augmentation Therapy with Atypical Antipsychotics in the Treatment of Depression

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000055058
Enrollment
76000
Registered
2024-08-01
Start date
2024-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

None listed

Sponsors

Other
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who had been diagnosed with depression at least once during the inclusion period and have a prescription for an antidepressant 2. Patients who were 18 years or older at the index date. The index date was the first day an antidepressant was prescribed after a new diagnosis of depression during the inclusion period 3. Patients who had been registered in the ledgers on insureds for more than one year before the new diagnosis of depression and for more than two and a half years after the index date 4. Patients who had a diagnosis of depression as described below in 1 or 2: 1) If the new diagnosis of depression was outpatient, there was at least one diagnosis of depression within one year after the index date 2) The new diagnosis of depression was diagnosed during hospitalization

Exclusion criteria

Exclusion criteria: Patients who met the following criteria within the year prior to the new diagnosis of depression were excluded. 1. Patients who had been diagnosed with schizophrenia, schizoaffective disorder, or delusional disorder 2. Patients who had a prescription for an antidepressant 3. Patients who had a prescription for an antipsychotic 4. Patients who had been diagnosed with bipolar disorder 5. Patients who had a prescription for a mood stabilizer 6. Patients who had a diagnosis of organic mental disorders, including symptomatic ones 7. Patients who had a diagnosis of mental and behavioral disorders due to the use of psychoactive substances After the index date, cases that violate the following criteria will be excluded 1. There was no diagnosis of depression after the oldest month of treatment where the diagnosis was only bipolar disorder in the same patient ID + same treatment year and month 2. There was no diagnosis of depression after the oldest month of treatment where the diagnosis was only schizoaffective disorder and delusional disorder in the same patient ID + same treatment year and month 3. There was no diagnosis of depression after the oldest month of treatment where the diagnosis was only organic mental disorder in the same patient ID + same treatment year and month 4. Patients who had a prescription for Clozapine 5. Patients who had a prescription for long-acting injectable antipsychotics

Design outcomes

Primary

MeasureTime frame
Time from antidepressant prescription start date to initiation of atypical antipsychotic augmentation therapy Line of treatment from antidepressant prescription start date to start of atypical antipsychotic augmentation therapy

Countries

Japan

Contacts

Public ContactDaisuke Sekine

Medical Affairs Department Otsuka Pharmaceuticals Co., Ltd

sekined@otsuka.jp03-6717-1400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026